Home › Funds › PSP Research LLC › ARQT
PSP Research LLC position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
PSP Research LLC reported holding 10,000 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$264K, representing 0.18% of its reported portfolio and ranking #13 among its reported holdings. PSP Research LLC has disclosed ARQT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR
How PSP Research LLC's ARQT position evolved
PSP Research LLC first disclosed a stake in ARQT in Q4 2025 at 18,716 shares (US$544K). Across 4 filings, PSP Research LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 10,000 shares valued at US$264K — a reduction of -9,700 shares quarter over quarter.. Notable position changes include a 49% trim in Q3 2026 (shares rose 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 18.72K | $543.51K | New |
| Q1 2026 | 19.70K | $464.13K | Add |
| Q2 2026 | 19.70K | $516.53K | Hold |
| Q3 2026 | 10.00K | $264.30K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- Rubric Capital Management LP 8.27M sh · $216.88M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.37M sh · $36.00M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.27M sh · $33.18M · Q2 2026
- Jones Hill Capital LP 1.09M sh · $28.57M · Q2 2026
- FISHMAN JAY A LTD/MI 595.00K sh · $15.60M · Q2 2026
More on PSP Research LLC
FAQ
How long has PSP Research LLC held ARQT?
PSP Research LLC has disclosed ARQT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is PSP Research LLC's current position in ARQT?
As of Q3 2026, PSP Research LLC holds 10.00K shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $264.30K, representing 0.18% of its reported portfolio and ranking #13.
Has PSP Research LLC been buying or selling ARQT?
In the latest 13F filing (Q3 2026), PSP Research LLC reduced its position in ARQT.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.